I think she is going to figure it out.....Well if she is willing to hang out with you you might want to hold tight :-)! Bird (Girl) in the hand is better than 2 in the bush? Bush? I guess we are back to square one.
I agree..... waiting for financing to be completed and want to see participation from current insiders if any on secondary. Hoping panel review date helps us turn the corner. When? Maybe as early as Oct or as late as Dec?
Masterful plan by insiders? Funds will be used to pay down the debt and fund operations. More importantly, now insiders can participate on the secondary and buy shares very cheap. The stock corrected as news become selectively "available" about the 45mm shares offering. Now insiders can add to large positions ahead of the FDA approval and large orders in Q4? I bet their % ownership increases after the secondary. Seems like I am reading "The Prince". Anyhow, I want to participate on the secondary or add after completion if insiders significantly add to their positions as I expect. I am hoping 30-31 cents accounts for most or all of the dilution. Anyhow, I see a silver lining on the offering as I expect it will mark a bottom.
Let's follow the big money. We are very oversold. The "bad news" is out. If insiders significantly add to their GTHP positions on the secondary, I think that is our green light. Thoughts?
So it is my "negative" attitude why the stock is down? Really? I am just pointing out the S1, the 45mm shares for sale, calling Alison Zeigler for confirmation, etc.... but it is my negative attitude taking the stock down. Wow!
I mostly agree. I think the stock has absorbed a lot of bad news lately and hopefully it is close to a bottom. I have a theory about this secondary. Cartwright is a puppet for large insiders.
John bad timing with your rant about Cartwright and dilution. I guess they had no choice. The market knew about the offering and "corrected" the shares to 30 cents. The bad news is now out. Maybe be can reach a bottom. I think it gets approval and it is worth much more than 30 cents. Anyhow, hopefully the bottom is near and we are about to get some larger orders and FDA approval in early 2015. Terrible last 4 weeks. stock is very oversold. let's hope for the best.
I have confirmation from Alison Zeigler. Up to 45mm shares. Well GTHP already priced most or all of the dilution. Now we know why the stock plunged to 31-32 cents a month ago.
S1. Up to 45mm shares. Assuming 35 cents it dilutes the stock to @30 cents. Not sure they can get 35 cents. I guess they had no choice. i though the small arrangements were suppose to help us get to FDA. A bridge too far. Now you know why I was disappointed with the 30 day delay refiling the PMA.
Dilution in net tangible book value goes to 28.4 cents to shareholders assuming a price of issue of 36 cents (Prospectus).
The information in this prospectus is not complete and may be changed. We may not sell or offer these securities until the registration statement filed with the Securities and Exchange Commission is declared effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.
Subject to completion, dated September 12, 2014
45,000,000 Shares of Common Stock
Shares of Common Stock
Warrants to Purchase up to ￼ Shares of Common Stock
Shares of Common Stock Underlying the Warrants of
Guided Therapeutics, Inc.